Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
Recruiting · NCT07712029 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive | Advanced Refractory Solid Tumors; EGFR Gene Overexpression | Recruiting | Phase 2 | 2026-07-17 | NCT07712029 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Lepu Biopharma Co., Ltd. | 15 |
| Tianjin Medical University Second Hospital | 50 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical Unversity Second Hospital | Tianjin | China | 6 |